Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01620463
Recruitment Status : Completed
First Posted : June 15, 2012
Last Update Posted : January 24, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : March 2003
  Study Completion Date : March 2003
Publications of Results:
Kageyama S, Hirao K, Shimizu A, Matsumura Y, Zdravkovic M, Rasmussen MF, Irie S. Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long-acting human GLP-1 analogue - Phase 1 studies in Japanese healthy subjects with type 2 diabetes. Endocrinology and Diabetology 2007; 24 (6): 95-104